
Molbio Diagnostics shares will debut on the NSE and BSE on Monday, 17 August, after its initial public offering saw strong subscription of over 70 times. Grey market sources indicate a listing…
Molbio Diagnostics shares will debut on the NSE and BSE on Monday, 17 August, after its initial public offering saw strong subscription of over 70 times. Grey market sources indicate a listing premium of 15 to 20 percent over the issue price of Rs 807, with the grey market premium ranging between Rs 125 and Rs 156. The IPO had a price band of Rs 768-807 and raised Rs 200 crore via fresh issue along with an offer for sale of 91.66 lakh shares.
Market experts expect a listing gain of 14-16 percent. Mahesh M Ojha of Kantilal Chhaganlal Securities advised long-term investors to hold but short-term investors may consider partial profit booking. Harshal Dasani of INVasset PMS said beyond listing day, earnings delivery will determine returns. Proceeds from the fresh issue will fund a research facility, capital expenditure for offices and equipment, and general corporate purposes. Kotak Mahindra Capital, IIFL Capital, Jefferies India and Motilal Oswal were lead managers.
Sources (2): livemint.com, livemint.com (2)
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.